Integrated Environmental Technologies 10-Q 14 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 11, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	INTEGRATED ENVIRONMENTAL TECHNOLOGIES, LTD.
Entity Central Index Key	1,084,031
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		320,571,243
Trading Symbol	IEVM
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,016

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash	$ 229,144	$ 838,107
Accounts receivable, net	26,575	36,223
Prepaid expenses and other	65,452	14,948
Inventory	124,942	103,220
Total current assets	446,113	992,498
Property and equipment, net	204,198	245,621
Total assets	650,311	1,238,119
Current liabilities:
Accounts payable	540,568	209,774
Accrued expenses	339,146	199,893
Customer deposits	2,000	2,000
Convertible debentures	411,035	501,125
Note payable	15,935
Total current liabilities	1,308,684	912,792
Convertible debentures	1,346,236	788,501
Total liabilities	2,654,920	1,701,293
Commitments and contingencies
Stockholders’ deficiency:
Common stock, $.001 par value; 600,000,000 shares authorized; 320,571,243 and 311,404,576 shares, respectively, issued and outstanding	320,571	311,405
Additional paid-in capital	24,441,941	24,005,008
Accumulated deficit	(26,767,121)	(24,779,587)
Total stockholders’ deficiency	(2,004,609)	(463,174)
Total liabilities and stockholders’ deficiency	$ 650,311	$ 1,238,119

Consolidated Condensed Balance3

Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common stock, par value	$ .001	$ 0.001
Common stock, shares authorized	600,000,000	600,000,000
Common stock, shares issued	320,571,243	311,404,576
Common stock, shares outstanding	320,571,243	311,404,576

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues:
Sales	$ 50,430	$ 135,665	$ 151,567	$ 431,287
Leasing and licensing fees	6,000	6,000	18,000	18,000
Total revenues	56,430	141,665	169,567	449,287
Cost of sales	20,350	53,719	65,025	162,559
Gross profit	36,080	87,946	104,542	286,728
Operating expenses:
General and administrative	238,573	368,332	751,179	1,402,327
Sales and marketing	253,002	299,516	917,422	972,035
Research and development	40,041	37,200	141,249	230,379
Total operating expenses	531,616	705,048	1,809,850	2,604,741
Loss from operations	(495,536)	(617,102)	(1,705,308)	(2,318,013)
Other income (expense):
Interest income	47	136	142	526
Interest expense	(147,152)	(11,451)	(282,368)	(33,585)
Total other income (expense)	(147,105)	(11,315)	(282,226)	(33,059)
Net loss	$ (642,641)	$ (628,417)	$ (1,987,534)	$ (2,351,072)
Net loss per share, basic and diluted	$ 0	$ 0	$ (0.01)	$ (0.01)
Weighted average shares outstanding, basic and diluted	320,571,243	304,164,263	316,891,194	295,931,399

Consolidated Condensed Stateme5

Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net loss	$ (1,987,534)	$ (2,351,072)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	69,161	67,932
Stock-based compensation expense	5,108	454,543
Interest accreted on convertible debentures	158,937
Write-off of accounts receivable	6,610
Changes in operating assets and liabilities:
Accounts receivable	2,267	(32,030)
Inventory	(21,722)	(57,460)
Prepaid expenses and other	(50,504)	(12,536)
Other receivable		111,200
Accounts payable	331,565	295,494
Accrued expenses	147,953	(193,103)
Net cash used in operating activities	(1,338,159)	(1,717,032)
Cash flows used in investing activity:
Purchase of equipment	(27,738)	(21,852)
Cash flows from financing activities:
Proceeds from issuance of convertible debentures	603,500
Proceeds from sale of common stock, net of offering costs	137,500	1,913,950
Proceeds from issuance of note payable	24,650
Repayment of note payable	(8,716)	(46,546)
Net cash provided by financing activities	756,934	1,867,404
(Decrease) increase in cash	(608,963)	128,520
Cash - beginning of period	838,107	371,292
Cash - end of period	229,144	499,812
Supplemental disclosure of cash flow information:
Cash paid for interest	2,218	2,593
Cash paid for income taxes	650	900
Issuance of 171,428 shares of common stock as payment of director fees		12,000
Parts and materials inventory used in production equipment		55,951
Issuance of 1,055,303 shares of common stock as payment of offering costs related to private placements		56,000
Issuance of warrants to purchase 1,450,303 shares of common stock as payment of offering costs related to private placements		$ 47,100

Consolidated Condensed Stateme6

Consolidated Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Statement of Cash Flows [Abstract]
Common stock issued as payment of director fees		171,428
Common stock issued as payment offering costs related to private placements		1,055,303
Issuance of warrant to purchase of common stock shares as payment of offering costs related to private placements		1,450,303

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation The accompanying consolidated condensed financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant recurring operating losses and negative cash flows from operations. The Company had a working capital deficiency of $862,571 and an accumulated deficit of $26,767,121 as of September 30, 2016. The Company also has no lending relationships with commercial banks and is dependent on the completion of financings involving the private placement of its securities in order to continue operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company does not anticipate establishing any lending relationships with commercial banks in the foreseeable future due to its unprofitable operations and limited assets. The Company continues to execute its strategy of selling Excelyte ® ™

Inventory

Inventory	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Inventory	2. Inventory As of September 30, 2016 and December 31, 2015, inventory consisted of parts and materials totaling $124,942 and $103,220, respectively.

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	3. Property and Equipment As of September 30, 2016 and December 31, 2015, property and equipment, on a net basis, consisted of the following: September 30, 2016 December 31, 2015 Leasehold improvements $ 328,977 $ 328,977 Equipment 543,045 515,307 872,022 844,284 Less: Accumulated depreciation (667,824 ) (598,663 ) $ 204,198 $ 245,621

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2016
Payables and Accruals [Abstract]
Accrued Expenses	4. Accrued Expenses As of September 30, 2016 and December 31, 2015, accrued expenses consisted of the following: September 30, 2016 December 31, 2015 Accrued compensation $ 174,990 $ 116,455 Accrued interest (see Notes 5 and 6) 159,992 39,188 Accrued professional fees 4,000 22,000 Accrued consulting fees and other expenses 164 22,250 $ 339,146 $ 199,893

Convertible Debentures

Convertible Debentures	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Convertible Debentures	5. Convertible Debentures April 2007 Convertible Debenture On April 26, 2007, the Company issued a convertible debenture to an individual investor in the principal amount of $25,000. This convertible debenture matured on January 2, 2009 and remains unpaid and, as a result, such obligation can be placed in default by the holder. The convertible debenture accrues interest at a rate of 12% per annum and is convertible at any time into shares of the Company’s common stock at the option of the holder at a conversion price of $0.40 per share. An aggregate of 62,500 shares of the Company’s common stock can be issued upon the conversion of the outstanding principal amount due on this convertible debenture at the current conversion price of $0.40 per share. For the three and nine months ended September 30, 2016, the Company recorded $756 and $2,252, respectively, of interest expense related to this convertible debenture. For the three and nine months ended September 30, 2015, the Company recorded $756 and $2,244, respectively, of interest expense related to this convertible debenture. As of September 30, 2016 and December 31, 2015, the outstanding principal on this convertible debenture was $25,000, which was included as a component of current convertible debentures, and the accrued and unpaid interest was $18,694 and $16,441, respectively, which was included as a component of accrued expenses (see Note 4). Zanett Convertible Debenture On August 21, 2012, the Company issued to Zanett Opportunity Fund, Ltd. an 8% convertible debenture in the amount of $476,125 (the “Zanett August 2012 Debenture”). The Zanett August 2012 Debenture bears interest at a rate of 8% per annum, had a three-year term maturing on August 21, 2015 and was originally convertible into 4,761,250 of the Company’s common stock at a conversion price of $0.10 per share. Effective July 7, 2016, the Zanett August 2012 Debenture was amended to extend the maturity date to December 31, 2017 and reduce the conversion price to $0.07 per share. As a result of this amendment, the Zanett August 2012 Debenture is convertible into 6,801,786 shares of the Company’s common stock. For the three and nine months ended September 30, 2016, the Company recorded $9,601 and $28,594, respectively, of interest expense related to the Zanett August 2012 Debenture. For the three and nine months ended September 30, 2015, the Company recorded $9,601 and $28,489, respectively, of interest expense related to the Zanett August 2012 Debenture. As of September 30, 2016, the outstanding principal on the Zanett August 2012 Debenture was $476,125, which was included as a component of non-current convertible debentures, and the accrued and unpaid interest was $42,473, which was included as a component of accrued expenses (see Note 4). As of December 31, 2015, the outstanding principal on the Zanett August 2012 Debenture was $476,125, which was included as a component of current convertible debentures, and the accrued and unpaid interest was $13,880, which was included as a component of accrued expenses (see Note 4). November and December 2015 Convertible Debentures and Warrants On November 11, 2015, December 3, 2015 and December 18, 2015, the Company issued 12% convertible debentures (the “2015 Debentures”) in the aggregate principal amount of $997,222 to five institutional investors and three individual investors. In connection with the issuance of the 2015 Debentures, the Company issued warrants (the “2015 Debenture Warrants”) to purchase an aggregate of 7,123,014 shares of its common stock. The gross proceeds received in connection with these private placements were $897,500. The 2015 Debentures mature on the date that is two years from the issuance date, bear interest at a rate of 12% per annum and contain an original issue discount of 10% of the principal amount ($99,722 in aggregate). The entire principal amount of each of the 2015 Debentures is convertible at any time into shares of the Company’s common stock at the option of the respective debenture holder at a conversion price of $0.07 per share. An aggregate of 14,246,029 shares of the Company’s common stock can be issued pursuant to the 2015 Debentures at the current conversion price of $0.07 per share. The Company separately accounted for the liability and equity components of the 2015 Debentures based upon the relative fair value of the liability and equity components on the respective dates of issuance. As a result, the Company recorded a discount of $117,708 for the 2015 Debentures to account for the relative fair value attributable to the 2015 Debenture Warrants, which is being accreted as interest expense using the effective interest method over the respective two-year terms of each of the 2015 Debentures. In addition, the $99,722 original issue discount is also being accreted as interest expense using the effective interest method over the respective two-year terms of each of the 2015 Debentures. For the three and nine months ended September 30, 2016, the Company recorded a total of $57,565 ($27,402 accreted) and $171,443 ($81,610 accreted), respectively, of interest expense related to the 2015 Debentures. As of September 30, 2016 and December 31, 2015, $98,699 and $8,867, respectively, of interest due on the 2015 Debentures was accrued and recorded as a component of accrued expenses (see Note 4). As of September 30, 2016, the unamortized discount on the 2015 Debentures related to the fair value of the 2015 Debenture Warrants was $68,513, the unamortized discount on the 2015 Debentures related to the original issue discount was $58,598 and the net carrying value of the 2015 Debentures was $870,111, which was recorded as a component of non-current convertible debentures. As of December 31, 2015, the net carrying value of the 2015 Debentures was $788,501, which was recorded as a component of non-current convertible debentures. July 2016 Convertible Debentures and Warrants On July 14, 2016, the Company issued zero coupon secured convertible debentures to eight individual investors and one institutional investor (each a “July 2016 Debenture” and collectively, the “July 2016 Debentures”) in the aggregate principal amount of $670,557. In connection with the issuance of the July 2016 Debentures, the Company issued warrants (the “July 2016 Debenture Warrants”) to purchase an aggregate of 67,055,700 shares of its common stock. The gross proceeds received in connection with this private placement were $603,500. The July 2016 Debentures have a one-year term maturing on July 14, 2017, contain an original issue discount of 10% and are secured by the Company’s assets. The entire principal amount of a July 2016 Debenture is convertible at any time into shares of the Company’s common stock at the option of the holder at a conversion price of $0.01 per share (the “July 2016 Debenture Conversion Price”). If at any time subsequent to the issuance of the July 2016 Debentures and prior to the conversion of the July 2016 Debentures into shares of the Company’s common stock, the Company closes on a financing involving the issuance of convertible debentures or shares of its common stock with or at a per share conversion price or purchase price that is less than the July 2016 Debenture Conversion Price (the “Subsequent Financing Per Share Price”), then the July 2016 Debenture Conversion Price will be reduced to seventy-five percent (75%) of the Subsequent Financing Per Share Price. The quoted market price of the Company’s common stock on July 14, 2016 was $0.009 per share. An aggregate of 67,055,700 shares of the Company’s common stock can be issued pursuant to the July 2016 Debentures at the current conversion price of $0.01 per share. The July 2016 Debenture Warrants have a five-year term and provide the holders with the right to purchase an aggregate of 67,055,700 shares of the Company’s common stock at $0.01 per share. All of the shares of the Company’s common stock underlying the July 2016 Debenture Warrants are fully vested. The July 2016 Debenture Warrants contain a cashless exercise provision and are callable in the event the closing price of the Company’s common stock averaged over a period of ten consecutive trading days is equal to or greater than $0.04 per share. The exercise price of the July 2016 Debenture Warrants is subject to adjustment for stock dividends, stock splits, or similar events. The Company separately accounted for the liability and equity components of the July 2016 Debentures based upon the relative fair value of the liability and equity components on the respective dates of issuance. As a result, the Company recorded a discount of $294,794 for the July 2016 Debentures to account for the relative fair value attributable to the July 2016 Debenture Warrants, which is being accreted as interest expense using the effective interest method over the one-year term of the July 2016 Debentures. In addition, the $67,057 original issue discount is also being accreted as interest expense using the effective interest method over the one-year term of the July 2016 Debentures. For each of the three and nine months ended September 30, 2016, the Company recorded a total of $77,327 of accreted interest expense related to the July 2016 Debentures. As of September 30, 2016, the unamortized discount on the July 2016 Debentures related to the fair value of the July 2016 Debenture Warrants was $231,797, the unamortized discount on the July 2016 Debentures related to the original issue discount was $52,727 and the net carrying value of the July 2016 Debentures was $386,033, which was recorded as a component of current convertible debentures.

Note Payable

Note Payable	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Note Payable	6. Note Payable On May 9, 2016, the Company entered into a finance agreement with IPFS Corporation (“IPFS”). Pursuant to the terms of this finance agreement, IPFS loaned the Company the principal amount of $24,650, which amount would accrue interest at a rate of 9.6% per annum, in order to partially fund the payment of the premium of the Company’s director and officer liability insurance. The finance agreement requires the Company to make eleven monthly payments of $2,350, including interest, commencing May 15, 2016. For the three and nine months ended September 30, 2016, the Company recorded a total of $613 and $810, respectively, of interest expense related to this finance agreement. As of September 30, 2016, the outstanding principal balance related to this finance agreement was $15,935 and the accrued and unpaid interest was $127, which was included as a component of accrued expenses (see Note 4).

Stockholders' Deficiency

Stockholders' Deficiency	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Stockholders' Deficiency	7. Stockholders’ Deficiency Stock Options The Company currently has two stock option/stock compensation plans in place: the 2010 Stock Incentive Plan and the 2012 Equity Incentive Plan (collectively, the “Equity Incentive Plans”). The 2010 Stock Incentive Plan was approved by the stockholders in September 2010. The Company had reserved for issuance an aggregate of 10,000,000 shares of common stock under the 2010 Stock Incentive Plan. As of September 30, 2016, stock options to purchase 3,846,920 shares of the Company’s common stock were outstanding under the 2010 Stock Incentive Plan and 90,500 shares of the Company’s common stock had been issued under the 2010 Stock Incentive Plan. As a result of the adoption of the Company’s 2012 Equity Incentive Plan, no further awards are permitted under the 2010 Stock Incentive Plan. The 2012 Equity Incentive Plan was approved by the stockholders in May 2012. The original aggregate number of shares of common stock which could be awarded under the 2012 Equity Incentive Plan was 14,000,000 shares, subject to adjustment as provided in the 2012 Equity Incentive Plan. Effective January 29, 2016, as permitted under the 2012 Equity Incentive Plan, the Company’s board of directors increased the number of shares of common stock that could be awarded under the 2012 Equity Incentive Plan to 31,140,458 shares. As of September 30, 2016, options to purchase 2,518,150 shares of the Company’s common stock were outstanding under the 2012 Equity Incentive Plan and up to 28,622,308 shares of the Company’s common stock remain available for awards under the 2012 Equity Incentive Plan. Common stock grants and stock option awards under the Equity Incentive Plans were granted or issued at prices as determined by the Company’s compensation committee, but such prices were not less than the fair market value of the Company’s common stock on the date of grant or issuance. Stock options granted and outstanding to date consist of both incentive stock options and non-qualified stock options. A summary of stock option transactions under the Equity Incentive Plans during the nine months ended September 30, 2016 is set forth below: Stock Option Shares Weighted Average Exercise Price Per Common Share Aggregate Intrinsic Value Outstanding at December 31, 2015 8,365,070 $ 0.11 $ — Granted during the period — — — Exercised during the period — — — Terminated during the period (2,000,000 ) $ 0.04 — Outstanding at September 30, 2016 6,365,070 $ 0.13 $ — Exercisable at September 30, 2016 6,115,070 $ 0.13 $ — Exercisable at December 31, 2015 6,002,570 $ 0.13 $ — Information with respect to stock options outstanding and stock options exercisable as of September 30, 2016 is as follows: Stock Options Outstanding Stock Options Exercisable Exercise Price Number of Shares Available Under Outstanding Stock Options Weighted Average Exercise Price Per Common Share Weighted Average Remaining Contractual Life (Years) Number of Shares Available for Purchase Under Outstanding Stock Options Weighted Average Exercise Price Per Common Share Weighted Average Remaining Contractual Life (Years) $ 0.07 2,068,150 $ 0.07 3.5 2,068,150 $ 0.07 3.5 $ 0.08 450,000 $ 0.08 8.4 200,000 $ 0.08 8.4 $ 0.10 2,180,253 $ 0.10 2.4 2,180,253 $ 0.10 2.4 $ 0.20 833,333 $ 0.20 5.5 833,333 $ 0.20 5.5 $ 0.30 833,334 $ 0.30 5.5 833,334 $ 0.30 5.5 6,365,070 $ 0.13 4.0 6,115,070 $ 0.13 3.8 A summary of the non-vested shares subject to stock options granted under the Equity Incentive Plans as of September 30, 2016 is as follows: Stock Option Shares Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2015 2,362,500 $ 0.03 Granted during the period — — Vested during the period (112,500 ) $ 0.05 Terminated during the period (2,000,000 ) $ 0.03 Non-vested at September30, 2016 250,000 $ 0.05 As of September 30, 2016, there was $10,801 of total unrecognized compensation cost related to non-vested, stock-based compensation arrangements granted under the Equity Incentive Plans. That cost is expected to be recognized over a weighted average period of twenty months. Warrants to Purchase Common Stock A summary of warrant transactions during the nine months ended September 30, 2016 is as follows: Warrant Shares Weighted Average Exercise Price Per Common Share Aggregate Intrinsic Value Outstanding at December 31, 2015 25,454,701 $ 0.08 $ 3,459 Issued during the period 68,889,033 $ 0.01 — Exercised during the period — — — Terminated during the period (1,250,000 ) $ 0.05 — Outstanding at September 30, 2016 93,093,734 $ 0.03 $ — Exercisable at September 30, 2016 93,093,734 $ 0.03 $ — Exercisable at December 31, 2015 25,454,701 $ 0.08 $ 3,459 Warrants issued by the Company contain exercise prices that were approved by the Company’s board of directors. Such exercise prices are generally not less than the quoted market price of the Company’s common stock on the date of issuance. Warrants currently issued either vested immediately or over a period of up to three years and have a maximum term of ten years from the date of issuance. Information with respect to warrants outstanding and warrants exercisable at September 30, 2016 is as follows: Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number of Shares Available Under Outstanding Warrants Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Per Common Share Number of Shares Available for Purchase Under Outstanding Warrants Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Per Common Share $ 0.01 - 0.04 69,806,475 4.7 $ 0.01 69,806,475 4.7 $ 0.01 $ 0.06 - 0.07 9,844,244 2.8 $ 0.07 9,844,244 2.8 $ 0.07 $ 0.08 - 0.10 13,443,015 3.3 $ 0.10 13,443,015 3.3 $ 0.10 93,093,734 4.3 $ 0.03 93,093,734 4.3 $ 0.03 As of September 30, 2016, there were no non-vested shares subject to warrants and no unrecognized compensation cost related to warrants.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation During the three and nine months ended September 30, 2016 and 2015, the Company recorded stock-based compensation expense as follows: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 General and administrative $ 303 $ 7,080 $ 901 $ 261,331 Sales and marketing 1,413 4,084 4,207 137,036 Research and development — — — 56,176 $ 1,716 $ 11,164 $ 5,108 $ 454,543 For the three and nine months ended September 30, 2016, the Company recorded stock-based compensation expense related to stock options granted to employees of $1,716 and $5,108, respectively. For the three and nine months ended September 30, 2015, the Company recorded stock-based compensation expense related to common stock and stock options granted to employees and directors of $11,164 and $454,543, respectively. For each of the three and nine months ended September 30, 2016 and 2015, the Company did not record any stock-based compensation expense for non-employees.

Net Loss Per Common Share

Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Net Loss Per Common Share	9. Net Loss Per Common Share Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not deemed to be anti-dilutive. The dilutive effect of the outstanding stock options and warrants is computed using the treasury stock method. For the three and nine months ended September 30, 2016, diluted net loss per share did not include the effect of 6,365,070 shares of common stock issuable upon the exercise of outstanding stock options, 93,093,734 shares of common stock issuable upon the exercise of outstanding warrants and 88,166,015 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive. For the three and nine months ended September 30, 2015, diluted net loss per share did not include the effect of 8,365,070 shares of common stock issuable upon the exercise of outstanding stock options, 19,315,811 shares of common stock issuable upon the exercise of outstanding warrants and 4,823,750 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive.

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Components of Property and Equipment, on Net Basis	As of September 30, 2016 and December 31, 2015, property and equipment, on a net basis, consisted of the following: September 30, 2016 December 31, 2015 Leasehold improvements $ 328,977 $ 328,977 Equipment 543,045 515,307 872,022 844,284 Less: Accumulated depreciation (667,824 ) (598,663 ) $ 204,198 $ 245,621

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2016
Payables and Accruals [Abstract]
Components of Accrued Expenses	As of September 30, 2016 and December 31, 2015, accrued expenses consisted of the following: September 30, 2016 December 31, 2015 Accrued compensation $ 174,990 $ 116,455 Accrued interest (see Notes 5 and 6) 159,992 39,188 Accrued professional fees 4,000 22,000 Accrued consulting fees and other expenses 164 22,250 $ 339,146 $ 199,893

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Summary of Stock Option Transactions	A summary of stock option transactions under the Equity Incentive Plans during the nine months ended September 30, 2016 is set forth below: Stock Option Shares Weighted Average Exercise Price Per Common Share Aggregate Intrinsic Value Outstanding at December 31, 2015 8,365,070 $ 0.11 $ — Granted during the period — — — Exercised during the period — — — Terminated during the period (2,000,000 ) $ 0.04 — Outstanding at September 30, 2016 6,365,070 $ 0.13 $ — Exercisable at September 30, 2016 6,115,070 $ 0.13 $ — Exercisable at December 31, 2015 6,002,570 $ 0.13 $ —
Summary of Stock Options Outstanding and Exercisable	Information with respect to stock options outstanding and stock options exercisable as of September 30, 2016 is as follows: Stock Options Outstanding Stock Options Exercisable Exercise Price Number of Shares Available Under Outstanding Stock Options Weighted Average Exercise Price Per Common Share Weighted Average Remaining Contractual Life (Years) Number of Shares Available for Purchase Under Outstanding Stock Options Weighted Average Exercise Price Per Common Share Weighted Average Remaining Contractual Life (Years) $ 0.07 2,068,150 $ 0.07 3.5 2,068,150 $ 0.07 3.5 $ 0.08 450,000 $ 0.08 8.4 200,000 $ 0.08 8.4 $ 0.10 2,180,253 $ 0.10 2.4 2,180,253 $ 0.10 2.4 $ 0.20 833,333 $ 0.20 5.5 833,333 $ 0.20 5.5 $ 0.30 833,334 $ 0.30 5.5 833,334 $ 0.30 5.5 6,365,070 $ 0.13 4.0 6,115,070 $ 0.13 3.8
Summary of Non Vested Stock Options Granted	A summary of the non-vested shares subject to stock options granted under the Equity Incentive Plans as of September 30, 2016 is as follows: Stock Option Shares Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2015 2,362,500 $ 0.03 Granted during the period — — Vested during the period (112,500 ) $ 0.05 Terminated during the period (2,000,000 ) $ 0.03 Non-vested at September30, 2016 250,000 $ 0.05
Summary of Warrant Transactions	A summary of warrant transactions during the nine months ended September 30, 2016 is as follows: Warrant Shares Weighted Average Exercise Price Per Common Share Aggregate Intrinsic Value Outstanding at December 31, 2015 25,454,701 $ 0.08 $ 3,459 Issued during the period 68,889,033 $ 0.01 — Exercised during the period — — — Terminated during the period (1,250,000 ) $ 0.05 — Outstanding at September 30, 2016 93,093,734 $ 0.03 $ — Exercisable at September 30, 2016 93,093,734 $ 0.03 $ — Exercisable at December 31, 2015 25,454,701 $ 0.08 $ 3,459
Summary of Warrants Outstanding and Exercisable	Information with respect to warrants outstanding and warrants exercisable at September 30, 2016 is as follows: Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number of Shares Available Under Outstanding Warrants Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Per Common Share Number of Shares Available for Purchase Under Outstanding Warrants Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Per Common Share $ 0.01 - 0.04 69,806,475 4.7 $ 0.01 69,806,475 4.7 $ 0.01 $ 0.06 - 0.07 9,844,244 2.8 $ 0.07 9,844,244 2.8 $ 0.07 $ 0.08 - 0.10 13,443,015 3.3 $ 0.10 13,443,015 3.3 $ 0.10 93,093,734 4.3 $ 0.03 93,093,734 4.3 $ 0.03

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock-Based Compensation	During the three and nine months ended September 30, 2016 and 2015, the Company recorded stock-based compensation expense as follows: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 General and administrative $ 303 $ 7,080 $ 901 $ 261,331 Sales and marketing 1,413 4,084 4,207 137,036 Research and development — — — 56,176 $ 1,716 $ 11,164 $ 5,108 $ 454,543

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Working capital deficit	$ 862,571
Accumulated deficit	$ 26,767,121	$ 24,779,587

Inventory (Details Narrative)

Inventory (Details Narrative) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory	$ 124,942	$ 103,220

Property and Equipment - Compon

Property and Equipment - Components of Property and Equipment, on Net Basis (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Leasehold improvements	$ 328,977	$ 328,977
Equipment	543,045	515,307
Property and equipment, Gross	872,022	844,284
Less: Accumulated depreciation	(667,824)	(598,663)
Property and equipment, net	$ 204,198	$ 245,621

Accrued Expenses - Components o

Accrued Expenses - Components of Accrued Expenses (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Accrued compensation	$ 174,990	$ 116,455
Accrued interest (see Note 5 and 6)	159,992	39,188
Accrued professional fees	4,000	22,000
Accrued consulting fees and other expenses	164	22,250
Accrued liabilities, total	$ 339,146	$ 199,893

Convertible Debentures (Details

Convertible Debentures (Details Narrative) - USD ($)	Jul. 14, 2016	Aug. 21, 2012	Apr. 26, 2007	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 18, 2015	Nov. 11, 2015
Debt Instrument [Line Items]
Convertible debenture outstanding principal				$ 1,346,236		$ 1,346,236		$ 788,501
Proceeds from issuance of stock						137,500	$ 1,913,950
April 2007 Convertible Debenture [Member]
Debt Instrument [Line Items]
Convertible debenture issued, principal amount			$ 25,000
Convertible debenture, maturity date			Jan. 2, 2009
Convertible debenture, interest rate			12.00%
Convertible debenture, conversion price			$ 0.40
Common stock issued as payment on principal and interest on convertible debentures, shares			62,500
Interest expense related to convertible debenture				756	$ 756	2,252	2,244
Convertible debenture outstanding principal				25,000		25,000		25,000
Accrued and unpaid interest on convertible debt				18,694		$ 18,694		16,441
Debt maturity date			Jan. 2, 2009
Zanett August 2012 Debenture [Member]
Debt Instrument [Line Items]
Convertible debenture, maturity date		Aug. 21, 2015				Dec. 31, 2017
Common stock issued as payment on principal and interest on convertible debentures, shares		4,761,250				6,801,786
Interest expense related to convertible debenture				9,601	$ 9,601	$ 28,594	$ 28,489
Convertible debenture outstanding principal				476,125		476,125		476,125
Accrued and unpaid interest on convertible debt				$ 42,473		$ 42,473		$ 13,880
Debenture term						3 years
Debt maturity date		Aug. 21, 2015				Dec. 31, 2017
Zanett August 2012 Debenture [Member] | Zanett Opportunity Fund, Ltd [Member] | 8% Convertible Debenture [Member]
Debt Instrument [Line Items]
Convertible debenture issued, principal amount		$ 476,125
Convertible debenture, interest rate		8.00%
Convertible debenture, conversion price		$ 0.10
2015 Debenture Warrants [Member]
Debt Instrument [Line Items]
Debenture term								2 years
Number of warrants issued to purchase of common stock shares				7,123,014		7,123,014
Debt amortized discount				$ 68,513		$ 68,513
Amortization of discount								$ 117,708
Interest expense debt				$ 98,699		$ 98,699		8,867
2015 Debenture Warrants [Member] | Non Current [Member]
Debt Instrument [Line Items]
Convertible debenture, conversion price				$ 0.07		$ 0.07
Number of warrants issued to purchase of common stock shares				870,111		870,111
2015 Debenture Warrants [Member] | Minimum [Member]
Debt Instrument [Line Items]
Accrued and unpaid interest on convertible debt				$ 27,402		$ 27,402
2015 Debenture Warrants [Member] | Maximum [Member]
Debt Instrument [Line Items]
Accrued and unpaid interest on convertible debt				$ 81,610		$ 81,610
2015 Debentures [Member]
Debt Instrument [Line Items]
Convertible debenture issued, principal amount								$ 788,501	$ 997,222	$ 997,222
Convertible debenture, interest rate				12.00%		12.00%
Convertible debenture, conversion price				$ 0.07		$ 0.07
Common stock issued as payment on principal and interest on convertible debentures, shares						14,246,029
Interest expense related to convertible debenture				$ 57,565		$ 171,443
Debenture term						2 years
Proceeds from private placement						$ 897,500
Percentage of original issuance discount debt						10.00%
Debt amortized discount				58,598		$ 58,598
July 2016 Debenture [Member]
Debt Instrument [Line Items]
Debt aggregate principal	$ 670,557
Debt discount percent	75.00%
Quoted market price, per share	$ 0.009
Warrants exercisable price per share	0.01
Share issued, per share	$ 0.01
July 2016 Debenture [Member] | Warrant [Member]
Debt Instrument [Line Items]
Convertible debenture issued, principal amount				386,033		386,033
Convertible debenture, maturity date	Jul. 14, 2017
Interest expense related to convertible debenture				77,327		77,327
Debt amortized discount				231,797		$ 231,797
Interest expense debt	$ 67,057
Warrants issued to purchase number of common stock	67,055,700
Proceeds from issuance of stock	$ 603,500
Debt maturity date	Jul. 14, 2017
Warrants exercisable price per share	$ 0.04
Warrants term	5 years
Fair value of warrants	$ 294,794
Original issue discount				$ 52,727

Note Payable (Details Narrative

Note Payable (Details Narrative) - USD ($)	May 09, 2016	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Proceeds from notes			$ 24,650
Unpaid interest		$ 159,992	159,992		$ 39,188
Finance Agreement [Member]
Proceeds from notes	$ 24,650
Accured interest rate, percent	9.60%
Debt instrument monthly payments	$ 2,350
Interest expense		$ 613	$ 810
Unpaid interest	$ 127

Stockholders' Deficiency (Detai

Stockholders' Deficiency (Details Narrative)	9 Months Ended
	Sep. 30, 2016USD ($)shares
2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance	10,000,000
Issuance of stock option to purchases of common stock shares	3,846,920
Common stock stock shares issued under plan	90,500
Number of stock option shares issued upto shares	28,622,308
2012 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock stock shares issued under plan	14,000,000
Number of common stock shares award under plan	2,518,150
Number of common stock shares increased under plan	31,140,458
Recognized non vested over a weighted average period	20 months
Unrecognized compensation costs related to non vested | $	$ 10,801
Warrant [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant vested period	3 years
Warrant [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant vested period	10 years

Stockholders' Deficiency - Summ

Stockholders' Deficiency - Summary of Stock Option Transactions (Details)	9 Months Ended
	Sep. 30, 2016USD ($)$ / sharesshares
Equity [Abstract]
Stock Option Outstanding, Number, Beginning Balance | shares	8,365,070
Stock Option Granted during the period, Shares | shares
Stock Option Exercised during the period, Shares | shares
Stock Option Terminated during the period, Shares | shares	(2,000,000)
Stock Option Outstanding shares, Ending balance | shares	6,365,070
Stock Option Exercisable, Beginning balance | shares	6,002,570
Stock Option Exercisable, Ending balance | shares	6,115,070
Stock Option Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 0.11
Stock Option Grants in Period, Weighted Average Exercise Price
Stock Option Exercises in Period, Weighted Average Exercise Price
Stock OptionTerminated, Weighted Average Exercise Price	0.04
Stock Option Outstanding, Weighted Average Exercise Price, Ending balance	0.13
Stock Option Exercisable, Weighted Average Exercise Price, Beginning balance	0.13
Stock Option Exercisable, Weighted Average Exercise Price, Ending balance	$ 0.13
Stock Option Outstanding, Aggregate Intrinsic Value, Beginning balance | $
Stock Option Granted Aggregate Intrinsic Value
Stock Option Exercised Aggregate Intrinsic Value | $
Stock Option Outstanding, Aggregate Intrinsic Value, Ending balance | $
Stock Option Exercisable, Intrinsic Value Beginning balance | $
Stock Option Exercisable, Intrinsic Value Ending balance | $

Stockholders' Deficiency - Su28

Stockholders' Deficiency - Summary of Stock Options Outstanding and Exercisable (Details) - $ / shares	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Available Under Outstanding Stock Options	6,365,070	8,365,070
Weighted Average Exercise Price Per Common Share	$ 0.13	$ 0.11
Weighted Average Remaining Contractual Life (Years)	4 years
Number of Shares Available for Purchase Under Outstanding Stock Options	6,115,070	6,002,570
Weighted Average Exercise Price Per Common Share	$ 0.13	$ 0.13
Weighted Average Remaining Contractual Life (Years)	3 years 9 months 18 days
Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$ 0.07
Number of Shares Available Under Outstanding Stock Options	2,068,150
Weighted Average Exercise Price Per Common Share	$ 0.07
Weighted Average Remaining Contractual Life (Years)	3 years 6 months
Number of Shares Available for Purchase Under Outstanding Stock Options	2,068,150
Weighted Average Exercise Price Per Common Share	$ 0.07
Weighted Average Remaining Contractual Life (Years)	3 years 6 months
Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$ 0.08
Number of Shares Available Under Outstanding Stock Options	450,000
Weighted Average Exercise Price Per Common Share	$ 0.08
Weighted Average Remaining Contractual Life (Years)	8 years 4 months 24 days
Number of Shares Available for Purchase Under Outstanding Stock Options	200,000
Weighted Average Exercise Price Per Common Share	$ 0.08
Weighted Average Remaining Contractual Life (Years)	8 years 4 months 24 days
Range Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$ 0.10
Number of Shares Available Under Outstanding Stock Options	2,180,253
Weighted Average Exercise Price Per Common Share	$ 0.10
Weighted Average Remaining Contractual Life (Years)	2 years 4 months 24 days
Number of Shares Available for Purchase Under Outstanding Stock Options	2,180,253
Weighted Average Exercise Price Per Common Share	$ 0.10
Weighted Average Remaining Contractual Life (Years)	2 years 4 months 24 days
Range Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$ 0.20
Number of Shares Available Under Outstanding Stock Options	833,333
Weighted Average Exercise Price Per Common Share	$ 0.20
Weighted Average Remaining Contractual Life (Years)	5 years 6 months
Number of Shares Available for Purchase Under Outstanding Stock Options	833,333
Weighted Average Exercise Price Per Common Share	$ 0.20
Weighted Average Remaining Contractual Life (Years)	5 years 6 months
Range Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$ 0.30
Number of Shares Available Under Outstanding Stock Options	833,334
Weighted Average Exercise Price Per Common Share	$ 0.30
Weighted Average Remaining Contractual Life (Years)	5 years 6 months
Number of Shares Available for Purchase Under Outstanding Stock Options	833,334
Weighted Average Exercise Price Per Common Share	$ 0.30
Weighted Average Remaining Contractual Life (Years)	5 years 6 months

Stockholders' Deficiency - Su29

Stockholders' Deficiency - Summary of Non Vested Stock Options Granted (Details)	9 Months Ended
	Sep. 30, 2016$ / sharesshares
Equity [Abstract]
Stock Option Nonvested, Number, Beginning Balance | shares	2,362,500
Stock Option Granted during the period | shares
Stock Option Vested during the period | shares	(112,500)
Stock Option Terminated during the period | shares	(2,000,000)
Stock Option Non-vested Balance | shares	250,000
Stock Option Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 0.03
Stock Option Weighted Average Grant Date Fair Value Per Share, Granted | $ / shares
Stock Option Weighted Average Grant Date Fair Value Per Share, Vested | $ / shares	0.05
Stock Option Weighted Average Grant Date Fair Value Per Share, Terminated | $ / shares	0.03
Stock Option Weighted Average Grant Date Fair Value Per Share, Ending Balance | $ / shares	$ 0.05

Stockholders' Deficiency - Su30

Stockholders' Deficiency - Summary of Warrant Transactions (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2016USD ($)$ / sharesshares
Warrant Shares Outstanding | shares	25,454,701
Warrant Shares Issued during the period | shares	68,889,033
Warrant Shares Exercised during the period | shares
Warrant Shares Terminated during the period | shares	(1,250,000)
Warrant Shares Outstanding | shares	93,093,734
Warrant Shares Exercisable Beginning Balance | shares	93,093,734
Warrant Shares Exercisable Ending Balance | shares	25,454,701
Weighted Average Exercise Price Per Common Share Outstanding | $ / shares	$ 0.08
Weighted Average Exercise Price Per Common Share Issued during the period | $ / shares	0.01
Weighted Average Exercise Price Per Common Share Exercised during the period | $ / shares
Weighted Average Exercise Price Per Common Share Terminated during the period | $ / shares	0.05
Weighted Average Exercise Price Per Common Share Outstanding | $ / shares	0.03
Weighted Average Exercise Price Per Common Share Exercisable Beginning Balance | $ / shares	.03
Weighted Average Exercise Price Per Common Share Exercisable Ending Balance | $ / shares	$ 0.08
Aggregate Intrinsic Value Outstanding Beginning Balance | $	$ 3,459
Aggregate Intrinsic Value Issued during the period | $
Aggregate Intrinsic Value Exercised during the period | $
Aggregate Intrinsic Value Terminated during the period | $
Aggregate Intrinsic Value Outstanding Ending Balance | $
Aggregate Intrinsic Value Exercisable Beginning Balance | $
Aggregate Intrinsic Value Exercisable Ending Balance | $	$ 3,459

Stockholders' Deficiency - Su31

Stockholders' Deficiency - Summary of Warrants Outstanding and Exercisable (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2016$ / sharesshares
Number of Shares Available Under Outstanding Stock Options/ Warrants | shares	93,093,734
Weighted Average Remaining Contractual Life (Years)	4 years 3 months 18 days
Weighted Average Exercise Price Per Common Share	$ 0.03
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants | shares	93,093,734
Weighted Average Remaining Contractual Life (Years)	4 years 3 months 18 days
Weighted Average Exercise Price Per Common Share	$ 0.03
Range One [Member]
Range of Exercise Prices, Lower Limit	.01
Range of Exercise Prices, Upper Limit	$ 0.04
Number of Shares Available Under Outstanding Stock Options/ Warrants | shares	69,806,475
Weighted Average Remaining Contractual Life (Years)	4 years 8 months 12 days
Weighted Average Exercise Price Per Common Share	$ 0.01
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants | shares	69,806,475
Weighted Average Remaining Contractual Life (Years)	4 years 8 months 12 days
Weighted Average Exercise Price Per Common Share	$ 0.01
Range Two [Member]
Range of Exercise Prices, Lower Limit	0.06
Range of Exercise Prices, Upper Limit	$ 0.07
Number of Shares Available Under Outstanding Stock Options/ Warrants | shares	9,844,244
Weighted Average Remaining Contractual Life (Years)	2 years 9 months 18 days
Weighted Average Exercise Price Per Common Share	$ 0.07
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants | shares	9,844,244
Weighted Average Remaining Contractual Life (Years)	2 years 9 months 18 days
Weighted Average Exercise Price Per Common Share	$ 0.07
Range Three [Member]
Range of Exercise Prices, Lower Limit	0.08
Range of Exercise Prices, Upper Limit	$ 0.10
Number of Shares Available Under Outstanding Stock Options/ Warrants | shares	13,443,015
Weighted Average Remaining Contractual Life (Years)	3 years 3 months 18 days
Weighted Average Exercise Price Per Common Share	$ 0.10
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants | shares	13,443,015
Weighted Average Remaining Contractual Life (Years)	3 years 3 months 18 days
Weighted Average Exercise Price Per Common Share	$ 0.10

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Stock-based compensation expense related to stock options and warrants	$ 1,716			$ 11,164	$ 5,108	$ 454,543
Employees [Member]
Stock-based compensation expense related to stock options and warrants		$ 1,716			$ 5,108
Employees and Directors [Member]
Stock-based compensation expense related to stock options and warrants			$ 11,164			$ 454,543

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock-Based Compensation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 1,716	$ 11,164	$ 5,108	$ 454,543
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	303	7,080	901	261,331
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	1,413	4,084	4,207	137,036
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense				$ 56,176

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details Narrative) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Outstanding Stock Options [Member]
Anti-dilutive	6,365,070	8,365,070	6,365,070	8,365,070
Outstanding Warrants [Member]
Anti-dilutive	93,093,734	19,315,811	93,093,734	19,315,811
Conversion of Convertible Debt [Member]
Anti-dilutive	88,166,015	4,823,750	88,166,015	4,823,750